PROCEPT BioRobotics (US:PRCT)2026-02-26 14:02PROCEPT BioRobotics 2026 Investor Day Summary Company Overview - Company: PROCEPT BioRobotics (NasdaqGM:PRCT) - Industry: Medical Technology, specifically focused on urology and BPH (Benign Prostatic Hyperplasia) treatment Key Points and Arguments Market Opportunity - Approximately 400,000 patients undergo prostate procedures annually, with only 10% market penetration by PROCEPT, indicating significant growth potential [2][3] - There are 8 million men seeking therapy for BPH, many dissatisfied with current drug treatments [2] - Over 1 million men discontinue medication annually due to ineffectiveness or side effects, presenting an additional opportunity [3] Technology and Clinical Evidence - PROCEPT has developed a game-changing technology for BPH treatment, with over 125,000 patients treated and 900 instruments installed globally [4][5] - The company emphasizes the importance of clinical evidence and aims to demonstrate effective execution in the field to drive market share [4] Reimbursement and Pricing Strategy - Transitioned to Category I reimbursement on January 1, 2026, which enhances the narrative around reimbursement and reduces previous uncertainties [5] - Handpiece pricing has seen a $300 increase, with expectations for average selling price (ASP) to reach $3,500 in 2026 [11] Revenue Management - Eliminated end-of-quarter volume discounts to stabilize revenue and improve ASP, leading to more predictable ordering patterns [8][9] - Anticipates a 1-to-1 ratio of handpiece sales to procedures, which is a conservative estimate given the addition of 200+ systems in 2026 [13][14] Sales Organization Changes - Integrated clinical and sales support teams under a single regional leader to optimize resource allocation and improve performance [15][17] - Aimed to reduce the time from purchase order to first procedures by 50% through better coordination [21] Strategic Focus Areas 1. Accelerating Procedure Growth: Targeting the 10% penetration in the surgical market and increasing awareness of Aquablation therapy [54][56] 2. Path to Profitability: Emphasizing the need for a clear path to profitability and improved margins [4][10] 3. Advancing Evidence and Innovation: Continuing to invest in clinical evidence and exploring new indications, including prostate cancer treatment [45][46] Patient-Centric Approach - Highlighting the importance of preserving urinary and sexual function while providing effective symptom relief [34][42] - Addressing the misalignment between physician assumptions and patient desires regarding BPH treatment [63][64] - Developing targeted patient education initiatives to increase awareness and understanding of Aquablation therapy [68] Competitive Landscape - Positioning Aquablation as a superior alternative to traditional TURP procedures, which have been around for over 100 years [31] - Emphasizing the unique benefits of Aquablation, including reduced complications and better long-term outcomes compared to other therapies [30][43] Future Growth Opportunities - Exploring leasing pilot programs to attract customers hesitant about capital expenditures [29] - Anticipating significant growth in the prostate cancer treatment market, leveraging existing technology and expertise [45][49] Additional Important Insights - The company is committed to educating both patients and clinicians about the benefits of Aquablation, aiming to shift perceptions and increase adoption [56][67] - The focus on durability and long-term outcomes is critical, as many contemporary BPH therapies struggle to maintain market momentum due to lack of sustained effectiveness [62] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics 2026 Investor Day, highlighting the company's growth potential, innovative technology, and commitment to patient-centered care.